Evaluation of Glucose Metrics in Adults with Type 1 Diabetes Switching to Insulin Glargine 300 U/mL: A Retrospective, Propensity-Score Matched Study

被引:0
作者
Charleer, Sara [1 ]
Fieuws, Steffen [2 ,3 ]
De Block, Christophe [4 ]
Bolsens, Nancy [4 ]
Nobels, Frank [5 ]
Mikkelsen, Kristian [6 ]
Mathieu, Chantal [1 ]
Gillard, Pieter [1 ,7 ,8 ]
机构
[1] Univ Hosp Leuven KU Leuven, Dept Endocrinol, Leuven, Belgium
[2] Katholieke Univ Leuven, Interuniv Inst Biostat & Stat Bioinformat, Leuven, Belgium
[3] Univ Hasselt, Leuven, Belgium
[4] Univ Antwerp, Univ Hosp Antwerp, Dept Endocrinol Diabetol Metab, Antwerp, Belgium
[5] OLV Hosp Aalst, Dept Endocrinol, Aalst, Belgium
[6] Sanofi Aventis Denmark AS, Copenhagen, Denmark
[7] Fonds Wetenschappelijk Onderzoek FWO, Brussels, Belgium
[8] Univ Hosp Leuven, Dept Endocrinol, Herestr 49, B-3000 Leuven, Belgium
关键词
Type; 1; diabetes; Continuous glucose monitoring; Real life; Long-acting insulin; GLYCEMIC CONTROL; HYPOGLYCEMIA; MELLITUS; PEOPLE; BASAL;
D O I
10.1089/dia.2023.0371
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To study real-world effect of switching to Insulin Glargine 300 U/mL (Gla-300) on glucose metrics in people with type 1 diabetes. Methods: This retrospective secondary-use study compared 151 adults who switched to Gla-300 from first-generation long-acting insulins (Switchers) to 281 propensity-score matched controls (Non-switchers) who continued first-generation long-acting insulins. Primary endpoint was difference in time in range (TIR) evolution. A fictive "switching" date was assigned to Non-switchers to facilitate between-group comparisons. Results: In the period before switching, TIR decreased numerically for people in whom Gla-300 was eventually initiated (-0.05%/month [-0.16 to 0.07]), while it increased for matched controls (0.08%/month [0.02 to 0.015]; between-group difference P = 0.047). After Gla-300-initiation, Switchers had similar TIR increase compared to Non-switchers (P = 0.531). Switchers used higher basal dose than before switch (Delta 0.012 U/[kg center dot d] [0.006 to 0.018]; P < 0.0001). Conclusion: In real-life, Gla-300 was typically initiated in people where TIR was decreasing, which was reversed after switch using slightly higher basal insulin dose.
引用
收藏
页码:488 / 493
页数:6
相关论文
共 20 条
  • [1] Continuous glucose monitoring and metrics for clinical trials: an international consensus statement
    Battelino, Tadej
    Alexander, Charles M.
    Amiel, Stephanie A.
    Arreaza-Rubin, Guillermo
    Beck, Roy W.
    Bergenstal, Richard M.
    Buckingham, Bruce A.
    Carroll, James
    Ceriello, Antonio
    Chow, Elaine
    Choudhary, Pratik
    Close, Kelly
    Danne, Thomas
    Dutta, Sanjoy
    Gabbay, Robert
    Garg, Satish
    Heverly, Julie
    Hirsch, Irl B.
    Kader, Tina
    Kenney, Julia
    Kovatchev, Boris
    Laffel, Lori
    Maahs, David
    Mathieu, Chantal
    Mauricio, Didac
    Nimri, Revital
    Nishimura, Rimei
    Scharf, Mauro
    Del Prato, Stefano
    Renard, Eric
    Rosenstock, Julio
    Saboo, Banshi
    Ueki, Kohjiro
    Umpierrez, Guillermo E.
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2023, 11 (01) : 42 - 57
  • [2] Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
    Battelino, Tadej
    Danne, Thomas
    Bergenstal, Richard M.
    Amiel, Stephanie A.
    Beck, Roy
    Biester, Torben
    Bosi, Emanuele
    Buckingham, Bruce A.
    Cefalu, William T.
    Close, Kelly L.
    Cobelli, Claudio
    Dassau, Eyal
    DeVries, J. Hans
    Donaghue, Kim C.
    Dovc, Klemen
    Doyle, Francis J.
    Garg, Satish
    Grunberger, George
    Heller, Simon
    Heinemann, Lutz
    Hirsch, Irl B.
    Hovorka, Roman
    Jia, Weiping
    Kordonouri, Olga
    Kovatchev, Boris
    Kowalski, Aaron
    Laffel, Lori
    Levine, Brian
    Mayorov, Alexander
    Mathieu, Chantal
    Murphy, Helen R.
    Nimri, Revital
    Norgaard, Kirsten
    Parkin, Christopher G.
    Renard, Eric
    Rodbard, David
    Saboo, Banshi
    Schatz, Desmond
    Stoner, Keaton
    Urakami, Tatsuiko
    Weinzimer, Stuart A.
    Phillip, Moshe
    [J]. DIABETES CARE, 2019, 42 (08) : 1593 - 1603
  • [3] New Insulin Glargine 300 Units.mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units.mL-1
    Becker, Reinhard H. A.
    Dahmen, Raphael
    Bergmann, Karin
    Lehmann, Anne
    Jax, Thomas
    Heise, Tim
    [J]. DIABETES CARE, 2015, 38 (04) : 637 - 643
  • [4] Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections
    Bergenstal, RichardM.
    Bailey, Timothy S.
    Rodbard, David
    Ziemen, Monika
    Guo, Hailing
    Muehlen-Bartmer, Isabel
    Ahmann, Andrew J.
    [J]. DIABETES CARE, 2017, 40 (04) : 554 - 560
  • [5] Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal and Impaired Awareness of Hypoglycemia
    Charleer, Sara
    De Block, Christophe
    Bolsens, Nancy
    Van Huffel, Liesbeth
    Nobels, Frank
    Mathieu, Chantal
    Gillard, Pieter
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2023, 25 (04) : 231 - 241
  • [6] Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study
    Charleer, Sara
    De Block, Christophe
    Van Huffel, Liesbeth
    Broos, Ben
    Fieuws, Steffen
    Nobels, Frank
    Mathieu, Chantal
    Gillard, Pieter
    [J]. DIABETES CARE, 2020, 43 (02) : 389 - 397
  • [7] Patient-Reported Outcomes with Insulin Glargine 300 U/mL in People with Type 2 Diabetes: The MAGE Multicenter Observational Study
    Colin, Ides M.
    Alexandre, Kathy
    Bruhwyler, Jacques
    Scheen, Andre
    Verhaegen, Ann
    [J]. DIABETES THERAPY, 2020, 11 (08) : 1835 - 1847
  • [8] Lower risk of severe hypoglycaemia with insulin glargine 300 U/mLversus glargine 100 U/mLin participants with type 1 diabetes: Ameta-analysisof6-monthphase 3 clinical trials
    Danne, Thomas
    Matsuhisa, Munehide
    Sussebach, Christian
    Goyeau, Harmonie
    Lauand, Felipe
    Niemoeller, Elisabeth
    Bolli, Geremia B.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (10) : 1880 - 1885
  • [9] ema, Summary Of Product Characteristics Remicade(R)
  • [10] Glycaemic control and hypoglycaemia during 12months of randomized treatment with insulin glargine 300U/mL versus glargine 100U/mL in people with type 1 diabetes (EDITION 4)
    Home, Philip D.
    Bergenstal, Richard M.
    Bolli, Geremia B.
    Ziemen, Monika
    Rojeski, Maria
    Espinasse, Melanie
    Riddle, Matthew C.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (01) : 121 - 128